Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.
2 reports, 1 independent
Updated Aug 3
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Supernus Pharmaceuticals, Bristol-Myers Squibb, and Merck are identified as operating within the branded pharmaceuticals segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
-
Bristol-Myers Squibb
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.
- Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Bristol-Myers Squibb has taken ownership of Celgene's drug.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
Coverage
Newest first; wire copies grouped- StockStorySupernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday afternoon. Her